Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-driven biotech momentum: Q2 revenue was $256.1M, up 32% YoY, EPS beat by a wide margin, LIFYORLI contributed $47.6M in its first quarter, and relacorilant NDA was resubmitted to the FDA. Shares are up about 33% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Gross Margins ⢠Strong Cash Conversion ⢠Rising Dilution Risk CORT has strong margins, cash generation, and low leverage, but its extreme valuation and share dilution risk warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support holding ⢠Rejection near $115 Support Level: $110â$111 Resistance Level: $114.90â$115.70 CORT remains bearish over the last month, with $110â$111 support critical and a reclaim of $115 needed to signal stabilization.
Sentiment & News
Key News Insights: ⢠Institutional Buying ⢠Lifyorli Approval ⢠Revenue Growth Corcept's strong institutional backing, accelerating revenue, and positive EU regulatory momentum for Lifyorli support growth prospects, though elevated valuation and recent share weakness warrant caution.
AI Summary
CORT's investment case has shifted to relacorilant oncology-launch execution: strong cash generation and ~98% gross margins can drive major upside if European approval and Lifyorli uptake scale rapidly, but its premium valuation leaves little room for reimbursement delays, slower adoption, or regulatory setbacksâmaking proof of launch traction essential before adding exposure.
Description
Corcept Therapeutics is a U.S.-based biopharmaceutical company that discovers, develops and commercializes drugs for severe metabolic, oncologic and neuropsychiatric conditions. It markets Korlym (mifepristone) for hyperglycemia secondary to endogenous Cushingâs syndrome in adults with type 2 diabetes or glucose intolerance who have not had successful surgery or are ineligible, and has clinical-stage programs including relacorilant for Cushingâs and combination studies with nab-paclitaxel in advanced ovarian tumors, alongside separate programs targeting prostate cancer, antipsychotic-induced weight gain and FKBP5-related diagnostics. Founded in 1998, the company is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 30 | Aug 6 | CORT | Corcept Therapeutics Incorporated | Catalyst-driven biotech momentum: Q2 revenue was $256.1M, up 32% YoY, EPS beat by a wide margin, LIFYORLI contributed $47.6M in its first quarter, and relacorilant NDA was resubmitted to the FDA. Shares are up about 33% over 21 trading days. | Closed | -8.8% |
| Jun 8 | Jun 15 | CORT | Corcept Therapeutics Incorporated | Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active. | Closed | +13.4% |